Rein Therapeutics Inc
RNTX
NASDAQ
Biotechnology
$0.81
USD
+0.02 (+2.35%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $67.66M
Volume 210.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-50.21M
TTM
— YoY
Operating Cash Flow
$-16.61M
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.6 | 2.6 | 3.8 | 2.0 | 2.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 28.7 | 0.0 |
Total Operating Expenses | 5.6 | 6.9 | 5.5 | 32.7 | 5.2 |
Operating Income | -5.6 | -6.9 | -5.5 | -32.7 | -5.2 |
EBITDA | -5.6 | -6.9 | -5.5 | -4.0 | -5.2 |
Other Income / Expense | 0.1 | 0.0 | -0.1 | -0.0 | -0.6 |
Total Other Income / Expense | 0.1 | 0.0 | -0.1 | -0.0 | -0.6 |
Income Before Income Taxes | -5.5 | -6.8 | -5.6 | -32.7 | -5.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | -0.7 | 0.0 |
Net Income | -5.5 | -6.8 | -5.6 | -32.0 | -5.8 |
Consolidated Net Income / Loss | -5.5 | -6.8 | -5.6 | -32.0 | -5.8 |
Net Income Attributable to Common Shareholders | -5.5 | -6.8 | -5.6 | -32.0 | -5.8 |
Basic EPS | -$0.25 | -$0.28 | -$0.21 | -$1.09 | -$0.19 |
Diluted EPS | -$0.25 | -$0.28 | -$0.21 | -$1.09 | -$0.19 |
Basic Shares Outstanding | 21.9M | 24.2M | 26.4M | 29.3M | 30.4M |
Diluted Shares Outstanding | 21.9M | 24.2M | 26.4M | 29.3M | 30.4M |